These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 16871570)

  • 61. Evolution of hepatic steatosis in patients with advanced hepatitis C: results from the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial.
    Lok AS; Everhart JE; Chung RT; Kim HY; Everson GT; Hoefs JC; Greenson JK; Sterling RK; Lindsay KL; Lee WM; Di Bisceglie AM; Bonkovsky HL; Ghany MG; Morishima C;
    Hepatology; 2009 Jun; 49(6):1828-37. PubMed ID: 19291787
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Viral kinetics can predict early response to alpha-interferon in chronic hepatitis C.
    Walsh KM; Good T; Cameron S; Thorburn D; McCruden EA; Mills PR; Morris AJ
    Liver; 1998 Jun; 18(3):191-5. PubMed ID: 9716230
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Performance of two HCV RNA assays during protease inhibitor-based triple therapy in patients with advanced liver fibrosis and cirrhosis.
    Maasoumy B; Hunyady B; Calvaruso V; Makara M; Vermehren J; Haragh A; Susser S; Bremer B; Cloherty G; Manns MP; Craxì A; Wedemeyer H; Sarrazin C
    PLoS One; 2014; 9(11):e110857. PubMed ID: 25389779
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Qualitative detection of hepatitis C virus RNA: comparison of analytical sensitivity, clinical performance, and workflow of the Cobas Amplicor HCV test version 2.0 and the HCV RNA transcription-mediated amplification qualitative assay.
    Krajden M; Ziermann R; Khan A; Mak A; Leung K; Hendricks D; Comanor L
    J Clin Microbiol; 2002 Aug; 40(8):2903-7. PubMed ID: 12149349
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Improvement of platelets after SVR among patients with chronic HCV infection and advanced hepatic fibrosis.
    van der Meer AJ; Maan R; Veldt BJ; Feld JJ; Wedemeyer H; Dufour JF; Lammert F; Duarte-Rojo A; Manns MP; Zeuzem S; Hofmann WP; de Knegt RJ; Hansen BE; Janssen HL
    J Gastroenterol Hepatol; 2016 Jun; 31(6):1168-76. PubMed ID: 26647353
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Successful HCV genotyping of previously failed and low viral load specimens using an HCV RNA qualitative assay based on transcription-mediated amplification in conjunction with the line probe assay.
    Comanor L; Elkin C; Leung K; Krajden M; Kronquist K; Nicolas K; Horansky E; deMedina M; Kittichai P; Sablon E; Ziermann R; Sherlock C
    J Clin Virol; 2003 Sep; 28(1):14-26. PubMed ID: 12927747
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Prediction of relapse after interferon therapy in hepatitis C virus-infected patients by the use of triple assay.
    El-Awady MK; Abdel Rahman MM; Ismail SM; Amr KS; Omran M; Mohamed SA
    J Gastroenterol Hepatol; 2003 Jan; 18(1):68-73. PubMed ID: 12519227
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Long-term outcomes of chronic hepatitis C patients with sustained virological response at 6 months after the end of treatment.
    Chavalitdhamrong D; Tanwandee T
    World J Gastroenterol; 2006 Sep; 12(34):5532-5. PubMed ID: 17006994
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Comparison of HCV RNA levels by branched DNA probe assay and by competitive polymerase chain reaction to predict effectiveness of interferon treatment for patients with chronic hepatitis C virus.
    Hayashi J; Kawakami Y; Nabeshima A; Kishihara Y; Furusyo N; Sawayama Y; Kinukawa N; Kashiwagi S
    Dig Dis Sci; 1998 Feb; 43(2):384-91. PubMed ID: 9512135
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Clinical significance of discordant positive hepatitis C virus transcription-mediated amplification following end of treatment response.
    Thadani A; Harley J; Rubin J; Lebovics E
    Dig Dis Sci; 2012 Jan; 57(1):239-42. PubMed ID: 21755300
    [TBL] [Abstract][Full Text] [Related]  

  • 71. [Detection of serum HCV RNA in patients with chronic hepatitis C by transcription mediated amplification and real-time reverse transcription polymerase chain reaction].
    Wu D; Liu F; Liu H; Dai L; Tan D
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2014 Jul; 39(7):664-72. PubMed ID: 25080913
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Herbal product use by persons enrolled in the hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial.
    Seeff LB; Curto TM; Szabo G; Everson GT; Bonkovsky HL; Dienstag JL; Shiffman ML; Lindsay KL; Lok AS; Di Bisceglie AM; Lee WM; Ghany MG;
    Hepatology; 2008 Feb; 47(2):605-12. PubMed ID: 18157835
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Hepatitis C Virus Core Antigen (HCVAg): an affordable assay to monitor the efficacy of treatment in DAAs era.
    Rossetti B; Loggi E; Raffaelli CS; Mercinelli S; Gandolfo C; Savellini GG; Galli S; Vitale G; Di Donato R; Vukotic R; Grandini E; Margotti M; Guarneri V; Furlini G; Re MC; De Luca A; Andreone P; Galli C; Cusi MG
    New Microbiol; 2021 Apr; 44(2):89-94. PubMed ID: 34151994
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Quantitative liver function tests improve the prediction of clinical outcomes in chronic hepatitis C: results from the Hepatitis C Antiviral Long-term Treatment Against Cirrhosis Trial.
    Everson GT; Shiffman ML; Hoefs JC; Morgan TR; Sterling RK; Wagner DA; Lauriski S; Curto TM; Stoddard A; Wright EC;
    Hepatology; 2012 Apr; 55(4):1019-29. PubMed ID: 22030902
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Predictive value of different hepatitis C serological assays in the treatment of chronic hepatitis C with interferon alpha.
    Kobayashi M; Chayama K; Arase Y; Tsubota A; Saitoh S; Suzuki Y; Kobayashi M; Kobayashi M; Ikeda K; Matsuda M; Koike H; Hashimoto M; Kumada H
    J Gastroenterol; 1999 Feb; 34(1):94-9. PubMed ID: 10204617
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Influence of sustained viral response on the regression of fibrosis and portal hypertension in cirrhotic HCV patients treated with antiviral triple therapy.
    Puente Á; Cabezas J; López Arias MJ; Fortea JI; Arias MT; Estébanez Á; Casafont F; Fábrega E; Crespo J
    Rev Esp Enferm Dig; 2017 Jan; 109(1):17-25. PubMed ID: 27990835
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Performance characteristics of a transcription-mediated nucleic acid amplification assay for qualitative detection of hepatitis C virus RNA.
    Ross RS; Viazov SO; Hoffmann S; Roggendorf M
    J Clin Lab Anal; 2001; 15(6):308-13. PubMed ID: 11793430
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Reversibility of hepatitis C virus-related cirrhosis.
    Pol S; Carnot F; Nalpas B; Lagneau JL; Fontaine H; Serpaggi J; Serfaty L; Bedossa P; Bréchot C
    Hum Pathol; 2004 Jan; 35(1):107-12. PubMed ID: 14745732
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Long-term follow-up of successful hepatitis C virus therapy: waning immune responses and disappearance of liver disease are consistent with cure.
    Hedenstierna M; Weiland O; Brass A; Bankwitz D; Behrendt P; Uhnoo I; Aleman S; Cardell K; Fryden A; Norkrans G; Eilard A; Glaumann H; Pietschmann T; Sällberg M; Brenndörfer ED
    Aliment Pharmacol Ther; 2015 Mar; 41(6):532-43. PubMed ID: 25627143
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Comparison of the VERSANT HCV RNA qualitative assay (transcription-mediated amplification) and the COBAS AMPLICOR hepatitis C virus test, version 2.0, in patients undergoing interferon-ribavirin therapy.
    Germer JJ; Zein NN; Metwally MA; Hoskin TL; Scott Harmsen W; Smith TF; Patel R
    Diagn Microbiol Infect Dis; 2003 Dec; 47(4):615-8. PubMed ID: 14711484
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.